Breaking News: Promising Phase II Results
Clinical Stage Biotech
NovelMed Therapeutics
We plan to lead the complement blockers market through our strong intellectual property, trade-secrets and know-how.
Breakthrough Therapies for Rare Diseases
NovelMed’s strategy to selectively target the Alternative Pathway has led to the development of several first-in-class antibody-based drugs that have shown promising results in Phase II clinical trials. We believe we can lead the rare disease market based on our superior mechanism of action and our efficient development strategy.
Promising Early Phase II Results
Our early Phase II proof-of-concept results for PNH patients are promising. The next steps of our development strategy include
- Manufacturing and Phase II activation of NM8074
- Subcutaneous (SC) development of 8074
- Starting Phase II trials in SC
- Screening and IND filings of additional indications using SC
Highly Differentiated Capability
- Highly selective ability to block Alternative Pathway
- Higher Safety and expectation of no Black-box warning
- Bette frequency of dosing
- Lower cost of production
Attractive Partnering/Investment Opportunity
- Robust pipeline of complement blockers, with two lead candidates NM5072 and NM8074
- Exciting proof-of-concept data from NM8074
- US FDA awarded Orphan Drug Designation
- Led by a pioneer and supported by the leading intellectual property in this space
- Addressable market $400B +
- Expected commercialization by 2027-2028